针刺治疗卵巢储备功能减退的临床随机对照试验

注册号:

Registration number:

ITMCTR2200005907

最近更新日期:

Date of Last Refreshed on:

2022-04-26

注册时间:

Date of Registration:

2022-04-26

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刺治疗卵巢储备功能减退的临床随机对照试验

Public title:

A randomized controlled trial of acupuncture in the treatment of ovarian reserve dysfunction

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺治疗卵巢储备功能减退的临床随机对照试验

Scientific title:

A randomized controlled trial of acupuncture in the treatment of ovarian reserve dysfunction

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200059136 ; ChiMCTR2200005907

申请注册联系人:

赵越梦

研究负责人:

杨洁

Applicant:

zhaoyuemeng

Study leader:

yangjie

申请注册联系人电话:

Applicant telephone:

13198532729

研究负责人电话:

Study leader's telephone:

13882296714

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1033242802@qq.com

研究负责人电子邮件:

Study leader's E-mail:

jenny_yang_jie@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

四川省成都市金牛区十二桥路37号

研究负责人通讯地址:

四川省成都市温江区柳台大道1166号

Applicant address:

No. 37, Shierqiao Road, Jinniu District, Chengdu, Sichuan

Study leader's address:

1166 Liutai Avenue, Wenjiang District, Chengdu, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

成都中医药大学

Applicant's institution:

Chengdu University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

(2021)科研伦审第(027)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

成都西囡妇科医院科研伦理委员会

Name of the ethic committee:

Scientific research ethics committee of Chengdu Xinan gynecological hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021/10/15 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

成都西囡妇科医院

Primary sponsor:

Chengdu Xinan gynecological hospital

研究实施负责(组长)单位地址:

四川省成都市锦江区毕昇路66号

Primary sponsor's address:

No. 66, Bisheng Road, Jinjiang District, Chengdu, Sichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

成都市

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都西囡妇科医院

具体地址:

四川省成都市锦江区毕昇路66号

Institution
hospital:

Chengdu Xinan gynecological hospital

Address:

No. 66, Bisheng Road, Jinjiang District, Chengdu, Sichuan

经费或物资来源:

四川省科技厅

Source(s) of funding:

Sichuan Provincial Department of science and technology

研究疾病:

卵巢储备功能减退

研究疾病代码:

Target disease:

ovarian reserve dysfunction

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

I期临床试验

Phase I clinical trial

研究目的:

评价针刺治疗DOR的有效性和安全性。

Objectives of Study:

The purpose of this study was to evaluate the efficacy and safety of acupuncture in the treatment of ovarian reserve dysfunction.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)20岁≤年龄<40岁; (2)符合DOR诊断标准; (3)自愿参加试验,并且签署知情同意书。

Inclusion criteria

(1) 20 years ≤ age < 40 years; (2) Meet the diagnostic criteria of ovarian reserve dysfunction; (3) Voluntarily participate in the trial and sign the informed consent form.

排除标准:

(1) 患者患严重的心、肝、肾等全身器质性病变导致难以实现妊娠的患者; (2) 合并影响受孕的先天性生殖器官发育异常,内膜息肉、子宫肌瘤,子宫内膜异位症、或其它器质性疾病。 (3) 合并多囊卵巢综合征、高催乳素血症、高雄激素血症者、甲状腺功能减退、慢性肾上腺皮质功能减退等疾病; (4) 存在严重消耗性疾病亦或是发展性恶性肿瘤; (5) 有出血倾向以及容易发生感染者,或患有严重过敏性?或皮肤有溃疡?瘢痕等禁止针刺的患者; (6) 预计入组后2个月内有IVF-ET计划者。 注:凡符合上述任何一条的患者,即应予以排除。

Exclusion criteria:

(1) Patients suffering from severe systemic organic diseases such as heart, liver and kidney, which makes it difficult to achieve pregnancy; (2) Combined with congenital reproductive organ development abnormalities affecting pregnancy, endometrial polyps, hysteromyomas, endometriosis, or other organic diseases. (3) Patients with polycystic ovary syndrome, hyperprolactinemia, hyperandrogenemia, hypothyroidism, chronic adrenocortical dysfunction and other diseases; (4) Severe wasting disease or developing malignant tumor; (5) Patients with bleeding tendency and prone to infection, or patients with severe allergies, or patients with skin ulcers, scars and other prohibited acupuncture; (6) IVF-ET planners are expected within 2 months after enrollment. Note: patients who meet any of the above conditions should be excluded.

研究实施时间:

Study execute time:

From 2022-04-22

To      2024-10-31

征募观察对象时间:

Recruiting time:

From 2022-04-26

To      2024-10-31

干预措施:

Interventions:

组别:

针刺组

样本量:

36

Group:

Acupuncture group

Sample size:

干预措施:

针刺

干预措施代码:

Intervention:

Acupuncture

Intervention code:

组别:

假针刺组

样本量:

36

Group:

sham acupuncture group

Sample size:

干预措施:

非穴位浅刺

干预措施代码:

Intervention:

Non acupoint shallow needling

Intervention code:

样本总量 Total sample size : 72

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都西囡妇科医院

单位级别:

二级

Institution/hospital:

Chengdu Xinan gynecological hospital

Level of the institution:

second level

测量指标:

Outcomes:

指标中文名:

动脉收缩期峰值血流速度

指标类型:

次要指标

Outcome:

Peak systolic blood flow velocity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

促卵泡生成素

指标类型:

次要指标

Outcome:

Follicle stimulating hormone

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胚胎种植率

指标类型:

次要指标

Outcome:

embryo implantation rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

早期妊娠丢失率

指标类型:

次要指标

Outcome:

early pregnancy loss rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

焦虑自评量表

指标类型:

次要指标

Outcome:

Self-Rating Anxiety Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抗缪勒管激素

指标类型:

次要指标

Outcome:

Anti Mullerian hormone

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

sustained pregnancy rate

指标类型:

次要指标

Outcome:

持续妊娠率

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床妊娠率

指标类型:

次要指标

Outcome:

Clinical pregnancy rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

促黄体生成素

指标类型:

次要指标

Outcome:

Luteinizing hormone

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

孕酮

指标类型:

次要指标

Outcome:

Prog

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

雌二醇

指标类型:

次要指标

Outcome:

Estradiol

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

获卵数

指标类型:

次要指标

Outcome:

egg number

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

窦卵泡计数

指标类型:

主要指标

Outcome:

antral follicle count

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

优质胚胎率

指标类型:

次要指标

Outcome:

high-quality embryo rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

收缩期/舒张期血流速度比

指标类型:

次要指标

Outcome:

Systolic / diastolic blood flow velocity ratio

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

可利用胚胎率

指标类型:

次要指标

Outcome:

Available embryo rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生化妊娠率

指标类型:

次要指标

Outcome:

biochemical pregnancy rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

动脉阻力指数

指标类型:

次要指标

Outcome:

Arterial resistance index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 20
Min age years
最大 40
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

符合本研究纳入标准的受试者纳入。签署知情同意书后,由研究者采用随机数字表进行随机。

Randomization Procedure (please state who generates the random number sequence and by what method):

Subjects who met the inclusion criteria of this study were included. After signing the informed consent form, the researchers used the random number table to conduct random.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不适用。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not applicable.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

不适用。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Not applicable.

数据管理委员会:

Data Managemen Committee:

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统